Page last updated: 2024-12-05

quinidine sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID656862
CHEMBL ID3707183
MeSH IDM0018342

Synonyms (42)

Synonym
cinchonan-9-ol, 6'-methoxy-, (9s)-, sulfate (2:1) (salt), dihydrate
quinidine sulfate (2:1) (salt) dihydrate
6-methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol hemisulfate hydrate
quinidine, hemisulfate, hydrate
quinidine sulfate monohydrate
quinidine, sulfate, hydrate (2:1:2)
quinidine sulfate hydrate
cinchonan-9-ol, 6'-methoxy-, (9s)-, sulfate (2:1) (salt), monohydrate
quinidine sulfate (2:1) (salt) monohydrate
(s)-[(4s,5r,7r)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanolsulfatedihydrate
bis((s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol) sulfuric acid dihydrate
S3751
quinidine sulfate [usp:jan]
j13s2394he ,
unii-j13s2394he
quinidex extentabs
quinidine sulfate (2:1) (salt), dihydrate [who-ip]
quinidine sulfate dihydrate [mi]
quinidine sulfate dihydrate
quinidini sulfas [who-ip latin]
quinidine sulfate [who-ip]
quinidine sulfate [usp-rs]
quinidine sulfate [usp monograph]
quinidine sulfate hydrate [jan]
quinidine sulfate [ep monograph]
quinidine sulfate [vandf]
quinidine sulfate [mart.]
quinidine sulfate [orange book]
quinidine sulphate dihydrate
quinidine sulfate component of avp-786
avp-786 component quinidine sulfate
quinidine sulfate dihydrate [who-dd]
CHEMBL3707183
J-200115
mfcd00149346
AS-72510
(s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid;dihydrate
DTXSID101017271
(s)-(6-methoxyquinolin-4-yl)((1s,2r,4s,5r)-5-vinylquinuclidin-2-yl)methanol sulfate hydrate(2:1:2)
CCG-270468
Q27281012
AKOS037748835
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.02000.00002.015110.0000AID254812; AID262947
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID172623Appearance of ectopic beat (EA) in rats tested for in vivo Antiarrhythmic activity against aconitine induced arrhythmias at a dose of 10 mg/kg by iv administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID172624Appearance of ectopic beat (EA) in rats tested for in vivo Antiarrhythmic activity against aconitine induced arrhythmias at a dose of 25 mg/kg by po administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID172630Ventricular tachycardia (VT) in rats tested for in vivo Antiarrhythmic activity against aconitine induced arrhythmias at a dose of 25 mg/kg by po administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID1253468Inhibition of recombinant human truncated SHIP1 using PI(3,4,5)P3diC8 at 1 mM after 30 mins by malachite green phosphatase release assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP).
AID75885Change in heart rate(HR) in guinea pig tested for in vivo antiarrhythmic activity against ouabain induced cardiac arrhythmias at a dose of 10 mg/kg by iv administration; value ranges from 17-18%1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID172625Cardiac arrest(CA) in rats tested for in vivo Antiarrhythmic activity against aconitine induced arrhythmias at a dose of 10 mg/kg by iv administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID172626Cardiac arrest(CA) in rats tested for in vivo Antiarrhythmic activity against aconitine induced arrhythmias at a dose of 25 mg/kg by po administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID172628Ventricular fibrillation (VF) in rats tested for in vivo Antiarrhythmic activity against aconitine induced arrhythmias at a dose of 25 mg/kg by po administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID171903Change in heart rate(HR) in rats tested for in vivo antiarrhythmic activity against aconitine induced arrhythmias at a dose of 25 mg/kg by po administration; value ranges from 11-17%1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID75888Change in heart rate(HR) in guinea pig tested for in vivo antiarrhythmic activity against ouabain induced cardiac arrhythmias at a dose of 20 mg/kg by po administration; value ranges from 18-27%1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID397122Inhibition of HIV1 RT
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID262947Inhibition of human CYP2D6 expressed in Escherichia coli JM1092006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.
AID75879Appearance of ectopic beat (EA) in guinea pig tested for in vivo antiarrhythmic activity against ouabain induced cardiac arrhythmias at a dose of 20 mg/kg by po administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID172629Ventricular tachycardia (VT) in rats tested for in vivo Antiarrhythmic activity against aconitine induced arrhythmias at a dose of 10 mg/kg by iv administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID254812Inhibitory concentration against human hepatic cytochrome P450 2D6 enzyme2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
AID172627Ventricular fibrillation (VF) in rats tested for in vivo Antiarrhythmic activity against aconitine induced arrhythmias at a dose of 10 mg/kg by iv administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID75878Appearance of ectopic beat (EA) in guinea pig tested for in vivo antiarrhythmic activity against ouabain induced cardiac arrhythmias at a dose of 10 mg/kg by iv administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID75880Cardiac arrest(CA) in rats guinea pig tested for in vivo antiarrhythmic activity against ouabain induced cardiac arrhythmias at a dose of 20 mg/kg by po administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID171902Change in heart rate(HR) in rats tested for in vivo antiarrhythmic activity against aconitine induced arrhythmias at a dose of 10 mg/kg by iv administration; value ranges from 18-30%1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID75881Cardiac arrest(CA) in guinea pig tested for in vivo antiarrhythmic activity against ouabain induced cardiac arrhythmias at a dose of 10 mg/kg by iv administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID75883Ventricular fibrillation (VF) in guinea pig tested for in vivo antiarrhythmic activity against ouabain induced cardiac arrhythmias at a dose of 20 mg/kg by po administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID19847Lipophilicity was determined1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID1253470Inhibition of recombinant human truncated SHIP2 using PI(3,4,5)P3diC8 at 1 mM after 30 mins by malachite green phosphatase release assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP).
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID77743Antiarrhythmic effect expressed as percent reduction of the maximal rate of stimulation for antiarrhythmic activity in guinea pig auricle at 8 uM1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
AID75882Ventricular fibrillation (VF) in guinea pig tested for in vivo antiarrhythmic activity against ouabain induced cardiac arrhythmias at a dose of 10 mg/kg by iv administration1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and SAR studies of 1-substituted-n-(4-alkoxycarbonylpiperidin-1-yl)alkanes as potent antiarrhythmic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]